Abstract
OBJECTIVE: To analyze the relationships between CD34 expression and several demographic, clinical and pathological features, in patients with histopathological evidence of low-grade epilepsy-associated tumors (LEATs) who underwent epilepsy surgery.
METHODS: We conducted a retrospective study enrolling 187 patients with LEATs who underwent surgery between January 2009 and June 2015 at eight Italian epilepsy surgery centers. All cases were histologically diagnosed according to the WHO classification of tumors of the central nervous system. Univariate and multivariate analyses were performed to identify variables associated with CD34 expression.
RESULTS: Ninety-five (50.8%) out of 187 patients were CD34 positive. At multivariate analysis, tumor type and duration of epilepsy were independently associated with CD34 expression. Ganglioglioma and pleomorphic xanthoastrocytoma were the histotypes with the strongest association with CD34 positivity, with an odds ratio (OR) of 9.2 and 10.4 respectively, compared to dysembryoplastic neuroepithelial tumors. Patients with a duration of epilepsy longer than 10 years had significantly higher chances to show CD34 expression, with an OR of 2.8 compared to those with a duration of epilepsy shorter than 2 years. Furthermore, at univariate analysis CD34 expression appeared significantly related to older age at surgery, higher AEDs intake, and female gender.
CONCLUSIONS: Our study suggests that CD34 expression holds promise as a useful biomolecular marker for LEATs patients, with evidence of a link with clinicopathological features. We confirmed the association between CD34 expression and tumor type and demonstrated a significantly higher probability of CD34 expression in patients with a longer duration of epilepsy, independently of histology.
| Original language | English |
|---|---|
| Number of pages | 8 |
| Journal | World Neurosurgery |
| DOIs | |
| Publication status | E-pub ahead of print - Oct 8 2018 |
Fingerprint
Cite this
CD34 expression in low-grade epilepsy-associated tumors : relationships with clinicopathological features. / Giulioni, Marco; Marucci, Gianluca; Cossu, Massimo; Tassi, Laura; Bramerio, Manuela; Barba, Carmen; Buccoliero, Anna Maria; Vornetti, Gianfranco; Zenesini, Corrado; Consales, Alessandro; De Palma, Luca; Villani, Flavio; Di Gennaro, Giancarlo; Vatti, Giampaolo; Zamponi, Nelia; Colicchio, Gabriella; Marras, Carlo Efisio.
In: World Neurosurgery, 08.10.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - CD34 expression in low-grade epilepsy-associated tumors
T2 - relationships with clinicopathological features
AU - Giulioni, Marco
AU - Marucci, Gianluca
AU - Cossu, Massimo
AU - Tassi, Laura
AU - Bramerio, Manuela
AU - Barba, Carmen
AU - Buccoliero, Anna Maria
AU - Vornetti, Gianfranco
AU - Zenesini, Corrado
AU - Consales, Alessandro
AU - De Palma, Luca
AU - Villani, Flavio
AU - Di Gennaro, Giancarlo
AU - Vatti, Giampaolo
AU - Zamponi, Nelia
AU - Colicchio, Gabriella
AU - Marras, Carlo Efisio
N1 - Copyright © 2018 Elsevier Inc. All rights reserved.
PY - 2018/10/8
Y1 - 2018/10/8
N2 - OBJECTIVE: To analyze the relationships between CD34 expression and several demographic, clinical and pathological features, in patients with histopathological evidence of low-grade epilepsy-associated tumors (LEATs) who underwent epilepsy surgery.METHODS: We conducted a retrospective study enrolling 187 patients with LEATs who underwent surgery between January 2009 and June 2015 at eight Italian epilepsy surgery centers. All cases were histologically diagnosed according to the WHO classification of tumors of the central nervous system. Univariate and multivariate analyses were performed to identify variables associated with CD34 expression.RESULTS: Ninety-five (50.8%) out of 187 patients were CD34 positive. At multivariate analysis, tumor type and duration of epilepsy were independently associated with CD34 expression. Ganglioglioma and pleomorphic xanthoastrocytoma were the histotypes with the strongest association with CD34 positivity, with an odds ratio (OR) of 9.2 and 10.4 respectively, compared to dysembryoplastic neuroepithelial tumors. Patients with a duration of epilepsy longer than 10 years had significantly higher chances to show CD34 expression, with an OR of 2.8 compared to those with a duration of epilepsy shorter than 2 years. Furthermore, at univariate analysis CD34 expression appeared significantly related to older age at surgery, higher AEDs intake, and female gender.CONCLUSIONS: Our study suggests that CD34 expression holds promise as a useful biomolecular marker for LEATs patients, with evidence of a link with clinicopathological features. We confirmed the association between CD34 expression and tumor type and demonstrated a significantly higher probability of CD34 expression in patients with a longer duration of epilepsy, independently of histology.
AB - OBJECTIVE: To analyze the relationships between CD34 expression and several demographic, clinical and pathological features, in patients with histopathological evidence of low-grade epilepsy-associated tumors (LEATs) who underwent epilepsy surgery.METHODS: We conducted a retrospective study enrolling 187 patients with LEATs who underwent surgery between January 2009 and June 2015 at eight Italian epilepsy surgery centers. All cases were histologically diagnosed according to the WHO classification of tumors of the central nervous system. Univariate and multivariate analyses were performed to identify variables associated with CD34 expression.RESULTS: Ninety-five (50.8%) out of 187 patients were CD34 positive. At multivariate analysis, tumor type and duration of epilepsy were independently associated with CD34 expression. Ganglioglioma and pleomorphic xanthoastrocytoma were the histotypes with the strongest association with CD34 positivity, with an odds ratio (OR) of 9.2 and 10.4 respectively, compared to dysembryoplastic neuroepithelial tumors. Patients with a duration of epilepsy longer than 10 years had significantly higher chances to show CD34 expression, with an OR of 2.8 compared to those with a duration of epilepsy shorter than 2 years. Furthermore, at univariate analysis CD34 expression appeared significantly related to older age at surgery, higher AEDs intake, and female gender.CONCLUSIONS: Our study suggests that CD34 expression holds promise as a useful biomolecular marker for LEATs patients, with evidence of a link with clinicopathological features. We confirmed the association between CD34 expression and tumor type and demonstrated a significantly higher probability of CD34 expression in patients with a longer duration of epilepsy, independently of histology.
U2 - 10.1016/j.wneu.2018.09.212
DO - 10.1016/j.wneu.2018.09.212
M3 - Article
C2 - 30308344
JO - World Neurosurgery
JF - World Neurosurgery
SN - 1878-8750
ER -